Ginsenoside Rg5 inhibits the proliferation of HeLa cell through cell cycle pathway

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cervical cancer remains a leading cause of cancer death in women globally.
• Ginsenoside Rg5's role in human cancer cell growth is recognized, but its precise mechanism of action is not well understood.
• Understanding the molecular pathways affected by Ginsenoside Rg5 is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the preliminary mechanism of Ginsenoside Rg5 in cervical cancer.
• To analyze the impact of Ginsenoside Rg5 on gene expression in HeLa cervical cancer cells.
• To identify potential molecular targets for Ginsenoside Rg5-mediated cervical cancer treatment.

Main Methods:

• Treatment of HeLa cells with Ginsenoside Rg5.
• Quantitative Reverse Transcription Polymerase Chain Reaction (RT-qPCR) to assess gene expression.
• Western Blotting to evaluate protein levels.
• RNA sequencing (RNA-seq) for comprehensive gene expression profiling.

Main Results:

• Consistent down-regulation of cell cycle pathway proteins was observed across RT-qPCR, Western Blotting, and RNA-seq analyses.
• Expression of Minichromosome Maintenance Complex Component 6 (MCM6), Cyclin A2 (CCNA2), Cyclin-dependent kinase 6 (CDK6), and Cell division cycle 6 (CDC6) was significantly reduced in treated HeLa cells.
• Minichromosome Maintenance Complex Component 6 (MCM6) showed the most substantial inhibitory effect.

Conclusions:

• Ginsenoside Rg5 treatment leads to a significant decrease in the expression of critical cell cycle regulators in cervical cancer cells.
• The down-regulation of MCM6, CCNA2, CDK6, and CDC6 suggests Ginsenoside Rg5 interferes with cell cycle progression.
• MCM6 emerges as a highly promising molecular target for the development of novel cervical cancer therapeutics.